Amphastar Pharmaceuticals, Inc. — Earnings Release 2016

May 9, 2016

8-K 1 amph-20160509x8k.htm 8-K HTML document created with Merrill Bridge 6.1.177.0 Created on: 5/9/2016 1:13:52 PM amph_Current_Folio_8K_Q1

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Da t e of Re port (Da t e of ea rli e st e v e nt Re port e d ) : M ay 9 , 2016

Amphastar Pharmaceuticals, Inc.

(E x a ct Na m e of Re gistr a nt a s S p e cifi e d in C h a rt e r )

Delaware	001-36509	33-0702205
(S t a t e or O th e r Jurisdiction of I ncorpor a tion )	(Commission File N umb e r )	(I.R.S. Employer I d e ntific a tion N umb e r )

11570 6th Street
Rancho Cucamonga, California	91730
( Addr e ss of Principal E x e cutiv e O ffic e s )	(Z ip C od e)

Re gistr a nt's t e l e phon e numb e r , including a r ea cod e : (909) 980-9484

Not Applicable

(F orm e r n ame or for me r a ddr e ss , if ch a ng e d sinc e l a st r e port )

C h e ck the a ppropri a t e box b e low if the F orm 8- K filing is int e nd e d to simultaneously s a tisfy the filing oblig a tion of the r e gistr a nt und e r a ny of the following provisions:

◻ Written communications pursu a nt to R ul e 425 und e r the Securities Act (17 CFR 230.425)

◻ S oliciting ma t e ri a l pursu a nt to R ul e 14a-12 und e r the Exchange Act (17 CFR 240.14a-12)

◻ P r e- commencement communications pursu a nt to R ul e 14 d -2( b ) und e r the Exchange Act (17 CFR 240.14 d -2( b ))

◻ P r e- commencement communications pursu a nt to R ul e 13e-4( c ) und e r the Exchange Act (17 CFR 240.13e-4( c ))

Item 2.02. Results of Operations and Financial Condition.

On M ay 9 , 2016 , Amphastar Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended March 31, 201 6 . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) E xhibits:

Exhibit No.	Description
99.1	P r e ss r e l ea s e, d a t e d Ma y 9 , 2016 , issu e d by Amphastar Pharmaceuticals, I nc .

SIGNATURE

P ursu a nt to the r e quir e m e nts of the Securities Exchange Act of 1934, the r e gistr a nt h a s duly caused this r e port to b e sign e d on its b e h a lf by the und e rsign e d h e r e unto duly a uthori ze d .

Da t e : Ma y 9 , 2016
By:	/ s/ WILLIAM J. PETERS
	W illi am J . Peters
	C hi e f F in a nci a l O ffic e r a nd Se nior V ic e P r e sid e nt

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release, dated Ma y 9 , 2016 , issued by Amphastar Pharmaceuticals, Inc .